Q3 2024 revenue was $1.2 million, up 52% from $0.8 million in Q3 2023. The increase in revenue was a result of an increase in Components sales of $0.7 million, partially offset by a decrease in ...

Deciding to expand your franchise concept internationally is a challenging one. Doing so can provide growth opportunities far ...

It now wants to attract the world’s smartest minds to come and collaborate with local, like-minded tech entrepreneurs; this ...

Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients ...

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company") today reported financial results for ...

In accordance with Alpha Modus' patent infringement action against The Kroger Company, filed in January 2024, the Company has ...

Efforts underway to expand participation access and connectivity to Abaxx Exchange and Clearinghouse in key jurisdictions ...

The Delhi High Court has issued an interim injunction against a UP-based contract manufacturer Alder Biochem using the mark Biochem, in an application filed by Zydus Healthcare Ltd. In an interim ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good afternoon and welcome to Oncolytics Biotech’s Third Quarter 2024 Conference Call. All participants are in a listen-only mode. There ...

People and Their Plants, a Community-Driven Study” offers slate of informational webinars to engage stakeholders in state's cannabis history ...

The Industry Innovation Forum Tallinn (IIFT), formerly European Film Forum Tallinn, Europe's leading executive insight summit ...

Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive ReS ...